AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15077292 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab + MTX
Number of subjects: 24
Study 15077292 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 24
Study 10869583 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient with SMA-proper lesion
Number of subjects: 6
Study 10869583 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 6
Study 9377616 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg
Number of subjects: 20
Study 9377616 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg
Number of subjects: 20
Study 9377616 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose 0.3 mg
Number of subjects: 20
Study 9377616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9377616 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 20
Study 9377616 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 20
Study 9377616 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose and Voglibose
Number of subjects: 20
Study 8385844 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (two doses + booster)
Number of subjects: 79
Study 8385844 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (booster dose)
Number of subjects: 79
Study 8385844 — intervention group
Group type: COMPARATOR
Intervention: Convalescents and ISG recipients
Number of subjects: 79
Study 3081020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine (group II) 3.6 +/- 0.6 micrograms kg‐1 min‐1
Number of subjects: 80
Study 3081020 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (group III) 31.1 +/- 2.6 micrograms kg‐1 min‐1
Number of subjects: 80
Study 3081020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (group IV) 1.7 +/- 0.2 microgram kg‐1 min‐1
Number of subjects: 80
Study 3081020 — intervention group
Group type: COMPARATOR
Intervention: Control group (I: no vasodilator)
Number of subjects: 80
Study 2455121 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine
Number of subjects: 12
Study 31228383 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex non-drug programs including exercise therapy, drinking balneotherapy, multivitamins, vibrotherapy, chromotherapy, melody therapy, aromatherapy, aeroionotherapy
Number of subjects: 330
Study 31228383 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 330
Study 28182741 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV)
Number of subjects: 406
Study 28182741 — intervention group
Group type: EXPERIMENTAL
Intervention: Human metapneumovirus (hMPV)
Number of subjects: 406
Study 28182741 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus
Number of subjects: 406
Study 28182741 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae
Number of subjects: 406
Study 28182741 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoplasma pneumoniae
Number of subjects: 406
Study 28182741 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for RSV
Number of subjects: 406
Study 28182741 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for influenza A
Number of subjects: 406
Study 28182741 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for HPIV-3 infection
Number of subjects: 406
Study 25420207 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (1 or 2 mg/d)
Number of subjects: 191
Study 25420207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 23279594 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope (GS)
Number of subjects: 8
Study 23279594 — intervention group
Group type: EXPERIMENTAL
Intervention: Karl Storz (KS)
Number of subjects: 8
Study 23279594 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 8
Study 21663680 — intervention group
Group type: EXPERIMENTAL
Intervention: High calorie high protein supplement for forty days in addition to their diet of choice
Number of subjects: 44
Study 21663680 — intervention group
Group type: COMPARATOR
Intervention: High protein milk during hospital stay in addition to their diet of choice
Number of subjects: 44
Study 18254132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuchal scan at 10 to 14 + 6 weeks followed by detailed morphology scan at 12 to 14 + 6 weeks
Number of subjects: 7642
Study 18254132 — intervention group
Group type: COMPARATOR
Intervention: Nuchal scan at 10 to 14 + 6 weeks followed by routine 16‐23‐week scan
Number of subjects: 7642
Study 16836625 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program including screening, patient education, drug therapy with paroxetine, and supportive contacts.
Number of subjects: 0
Study 16836625 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) where general practitioners were blind to the screening results and treatment was not restricted.
Number of subjects: 0
Study 15523172 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin group (20-ml saline-flush followed by 2 ml of 1,000 U/ml heparin-lock)
Number of subjects: 48
Study 15523172 — intervention group
Group type: COMPARATOR
Intervention: Saline group (20-ml saline-flush once a day for each lumen)
Number of subjects: 48
Study 15523172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 11199329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 375
Study 11199329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 11199329 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14 CC genotype
Number of subjects: 375
Study 11199329 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha AA genotype
Number of subjects: 375
Study 11199329 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6-174 CC genotype
Number of subjects: 375
Study 9261525 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron, dexamethasone, and their combination (exact dosages and duration not specified)
Number of subjects: 395
Study 8392825 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg granisetron
Number of subjects: 85
Study 8392825 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg granisetron
Number of subjects: 85
Study 8392825 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg granisetron
Number of subjects: 85
Study 8392825 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg granisetron
Number of subjects: 85
Study 3080282 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms qid (without antacid)
Number of subjects: 0
Study 3080282 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms qid (with limited antacid)
Number of subjects: 0
Study 3080282 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms qid (with limited antacid)
Number of subjects: 0
Study 3080282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28462574 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise program (12 weeks, 3 times per week, 45-60 minutes per session)
Number of subjects: 26
Study 28462574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 26704270 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 34
Study 26704270 — intervention group
Group type: COMPARATOR
Intervention: Standard bupivacaine
Number of subjects: 34
Study 25906974 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dosing strategy
Number of subjects: 120
Study 25906974 — intervention group
Group type: COMPARATOR
Intervention: Standardized dosing strategy
Number of subjects: 120
Study 23550716 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES 130 kDa/0.4)
Number of subjects: 30
Study 23550716 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate (RAC)
Number of subjects: 30
Study 20589264 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide with light activation (diode lamp, Luma Cool)
Number of subjects: 21
Study 20589264 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen peroxide without light activation
Number of subjects: 21
Study 20589264 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of light-treated hemi-arch
Number of subjects: 21
Study 20589264 — intervention group
Group type: COMPARATOR
Intervention: Comparison of non-light-treated hemi-arch
Number of subjects: 21
Study 18221925 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine episiotomy
Number of subjects: 446
Study 18221925 — intervention group
Group type: COMPARATOR
Intervention: Selective episiotomy
Number of subjects: 446
Study 17019663 — intervention group
Group type: EXPERIMENTAL
Intervention: Early warfarin administration (12 hr after TCC placement) with ticlopidine 250 mg/die
Number of subjects: 144
Study 17019663 — intervention group
Group type: COMPARATOR
Intervention: Warfarin administration after the first thrombosis/malfunction episode with ticlopidine 250 mg/die
Number of subjects: 144
Study 12730452 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (n = 9; age, 2-5 mo)
Number of subjects: 45
Study 12730452 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding plus modest supplementation with cow's milk-based formula (n = 16; age, 3-4 mo)
Number of subjects: 45
Study 12730452 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive formula feeding (n = 4; age, 3-4 mo)
Number of subjects: 45
Study 12730452 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding plus complementary foods (n = 16; age, 7 mo)
Number of subjects: 45
Study 10735893 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (Hfx RT) with concurrent low-dose daily cisplatin (6 mg/m²)
Number of subjects: 130
Study 10735893 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiation therapy (Hfx RT) alone
Number of subjects: 130
Study 9014627 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 82
Study 9014627 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 82
Study 1389517 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and folinic acid
Number of subjects: 0
Study 1389517 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 0
Study 2412041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily for 4 weeks
Number of subjects: 10
Study 2412041 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg twice daily for 4 weeks
Number of subjects: 10
Study 2412041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 10
Study 31433785 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (TT) at moderate intensity (60% HRR), 2 sessions of 30 minutes/week for 10 weeks
Number of subjects: 20
Study 31433785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treadmill training)
Number of subjects: 20
Study 29906251 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ/veliparib
Number of subjects: 104
Study 29906251 — intervention group
Group type: COMPARATOR
Intervention: TMZ/placebo
Number of subjects: 104
Study 26749220 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 3 g
Number of subjects: 21
Study 26749220 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 6 g (multiple-dose, once daily)
Number of subjects: 21
Study 26749220 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 9 g
Number of subjects: 21
Study 26749220 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 6 g
Number of subjects: 21
Study 26749220 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxue-Tongluo lyophilized powder for injection (HTLPI)
Number of subjects: 21
Study 24466245 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) 25 mg/kg
Number of subjects: 452
Study 24466245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 50 mg/kg
Number of subjects: 452
Study 23143762 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (OP)
Number of subjects: 80
Study 23143762 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by radiotherapy (OP & RT)
Number of subjects: 80
Study 23143762 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) alone
Number of subjects: 80
Study 23143762 — intervention group
Group type: EXPERIMENTAL
Intervention: No local therapy (noL)
Number of subjects: 80
Study 19022282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Facts Label pocket card and video explaining card use
Number of subjects: 56
Study 19022282 — intervention group
Group type: COMPARATOR
Intervention: Written materials (control group)
Number of subjects: 56
Study 17483007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (1000 kcal/d) portioned into five meals per day
Number of subjects: 12
Study 17483007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (1000 kcal/d) between 0900 and 1100 h
Number of subjects: 12
Study 17483007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (1000 kcal/d) between 1800 and 2000 h
Number of subjects: 12
Study 17483007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (1000 kcal/d)
Number of subjects: 12
Study 14750100 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended dialysis for 12 hours
Number of subjects: 39
Study 14750100 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous hemofiltration (CVVH) for 24 hours
Number of subjects: 39
Study 11591234 — intervention group
Group type: COMPARATOR
Intervention: MCT meal (15 g fat)
Number of subjects: 18
Study 11591234 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleate meal (50 g fat)
Number of subjects: 18
Study 11591234 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals with increasing unsaturation
Number of subjects: 18
Study 9702314 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile (PAN)
Number of subjects: 197
Study 9702314 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone
Number of subjects: 197
Study 9702314 — intervention group
Group type: COMPARATOR
Intervention: Both PAN and polysulfone
Number of subjects: 197
Study 7520210 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5 and 25 mg/day)
Number of subjects: 186
Study 7520210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 7520210 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 186
Study 2784585 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampon use
Number of subjects: 35
Study 2784585 — intervention group
Group type: COMPARATOR
Intervention: Napkin use
Number of subjects: 35
Study 31948507 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex multidisciplinary program for depression care in nursing homes
Number of subjects: 796
Study 31948507 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific program components used in treatment procedures
Number of subjects: 796
Study 31948507 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment procedures
Number of subjects: 796
Study 31948507 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring procedures
Number of subjects: 796
Study 31021980 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 35 mg orally twice a day for three months, in addition to conventional treatments for angina.
Number of subjects: 58
Study 31021980 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments for angina only.
Number of subjects: 58
Study 28499583 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (epirubicin 60 mg/m2 per day plus ifosfamide 3 g/m2 per day, repeated every 21 days)
Number of subjects: 287
Study 28499583 — intervention group
Group type: EXPERIMENTAL
Intervention: Histotype-tailored chemotherapy (various regimens based on histological subtype)
Number of subjects: 287
Study 28499583 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 287
Study 28499583 — intervention group
Group type: EXPERIMENTAL
Intervention: Histotype-tailored chemotherapy
Number of subjects: 287
Study 26944817 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-month low-magnitude high-frequency vibration (LMHFV)
Number of subjects: 59
Study 26944817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 59
Study 24183196 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed irrigation solution at 32°C ± 2°C (89.6°F ± 3.6°F)
Number of subjects: 166
Study 24183196 — intervention group
Group type: COMPARATOR
Intervention: Room temperature irrigation solution (Control)
Number of subjects: 166
Study 22099625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 116
Study 22099625 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 116
Study 22099625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 116
Study 22099625 — intervention group
Group type: COMPARATOR
Intervention: Esmolol vs Nicardipine
Number of subjects: 116
Study 19643224 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethyl methacrylate (PMMA) / double-cross linked PMMA fillers (35%/59% SR Antaris DCL, SR Postaris DCL)
Number of subjects: 28
Study 19643224 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental artificial tooth material (48%/46%)
Number of subjects: 28
Study 17399635 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (intermediate doses of 50-210 mg dexamethasone equivalent)
Number of subjects: 990
Study 17399635 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (lower doses up to 8 mg)
Number of subjects: 990
Study 17399635 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (higher doses 236-2850 mg)
Number of subjects: 990
Study 17399635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990
Study 16338449 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599
Study 16338449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study 12643410 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm cardioplegia
Number of subjects: 70
Study 12643410 — intervention group
Group type: COMPARATOR
Intervention: Tepid blood cardioplegia
Number of subjects: 70
Study 9652859 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation Oncologists (RO)
Number of subjects: 11
Study 9652859 — intervention group
Group type: COMPARATOR
Intervention: Radiologists
Number of subjects: 11
Study 9652859 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 11
Study 9604043 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time frame (48 hours)
Number of subjects: 200
Study 9604043 — intervention group
Group type: COMPARATOR
Intervention: Standard time frame (2 weeks)
Number of subjects: 200
Study 2008948 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.4-5.0 mg.kg-1
Number of subjects: 67
Study 2008948 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg.kg-1
Number of subjects: 67
Study 2008948 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1.0 mg.kg-1 or greater
Number of subjects: 67
Study 2008948 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2.0 mg.kg-1 or greater
Number of subjects: 67
Study 6800869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (low-dose, 375 mg/day)
Number of subjects: 763
Study 6800869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (high-dose, 750 mg/day)
Number of subjects: 763
Study 6800869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763
Study 6800869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chenodeoxycholic acid
Number of subjects: 763
Study 6800869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chenodeoxycholic acid (women)
Number of subjects: 763
Study 6800869 — intervention group
Group type: COMPARATOR
Intervention: Placebo (women)
Number of subjects: 763
Study 6800869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy
Number of subjects: 763
Study 31088090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DXM) 0.5 mcg/kg with 0.5% ropivacaine 20 mL
Number of subjects: 60
Study 31088090 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DXA) 8 mg with 0.5% ropivacaine 20 mL
Number of subjects: 60
Study 31088090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DXM)
Number of subjects: 60
Study 31088090 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DXA)
Number of subjects: 60
Study 29295513 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg/day vitD3
Number of subjects: 12
Study 29295513 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg/day 25OH‐D3
Number of subjects: 12
Study 29295513 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg/day vitD2
Number of subjects: 12
Study 25407846 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach
Number of subjects: 24
Study 25407846 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat germs
Number of subjects: 24
Study 25407846 — intervention group
Group type: EXPERIMENTAL
Intervention: Camembert cheese
Number of subjects: 24
Study 25407846 — intervention group
Group type: COMPARATOR
Intervention: Pteroylmonoglutamic acid
Number of subjects: 24
Study 27863273 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (2min post-delivery)
Number of subjects: 97
Study 27863273 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC) (<10s post-delivery)
Number of subjects: 97
Study 27863273 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 97
Study 22658512 — intervention group
Group type: EXPERIMENTAL
Intervention: Early salvage hormonal therapy (PSA≤10 ng/mL and absent distant metastases)
Number of subjects: 102
Study 22658512 — intervention group
Group type: COMPARATOR
Intervention: Late salvage hormonal therapy (PSA>10 ng/mL and absent distant metastases)
Number of subjects: 102